Molecular docking, dynamics, and ADME studies of new isatin derivatives as histone deacetylase (HDAC) inhibitors

Hanan Adil Salih; Rafid M. Hashim; Basma M. Abd Razik; Ghazi Al Jabal

doi:10.32947/ajps.v26i3.1395

Authors

Hanan Adil Salih Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
Rafid M. Hashim Department of Pharmaceutical Chemistry, College of Pharmacy, Uruk University, Baghdad, Iraq.
Basma M. Abd Razik Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
Ghazi Al Jabal Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biomedical Sciences, MAHSA University, Bandar Saujana Putra, 42610, Jen Jarom, Selangor, Malaysia

DOI:

https://doi.org/10.32947/ajps.v26i3.1395

Keywords:

isatin, histone deacetylase, isocyanate, molecular docking, molecular dynamic

Abstract

Histone deacetylase-2 (HDAC-2) is an important therapeutic target in cancer treatment. Isatin derivatives have attracted considerable interest in medicinal chemistry because of their diverse biological activities. The present study aimed to investigate a series of newly designed isatin derivatives as HDAC-2 inhibitors using computational approaches. Molecular docking was performed against HDAC-2 protein (3MAX) to evaluate the binding affinity and interactions of the proposed compounds. ADME analysis was performed to assess their pharmacokinetic and drug-likeness properties. The most promising derivative was subjected to molecular dynamics (MD) simulation for 200 ns to evaluate the stability of the protein–ligand complex and characterize key molecular interactions throughout the simulation period. Among the investigated compounds, Compound 2 exhibited the most favorable binding affinity toward HDAC-2 with a docking score of -9.866 kcal/mol, slightly exceeding that of the reference inhibitor SAHA -9.707 kcal/mol. The compound demonstrates stable interactions with binding site residues and maintained interaction with zinc ion. MD simulations demonstrated stable protein-ligand interactions, minimum structural fluctuations, and preservation of the overall protein secondary structure throughout the simulation. These findings suggest that Compound 2 could be a promising isatin-based scaffold for the development of new HDAC-2 inhibitors.

References

1. Feliu A, Anderson AS, Bauld L, Fernández E, Leitzmann M, Morris S, et al. European Code Against Cancer, –tobacco and nicotine containing products, second‐hand smoke, alcohol and cancer. Mol Oncol. 2026;20(1):6–27.

2. Mukhlif MM, Alwash AH, Harbi SM, Husein SA, Abbood MK, Yaseen HA. Molecular docking and molecular dynamic of new thioguanine derivatives as histone deacetylase inhibitors. Appl Chem Eng [Internet]. 2025;8(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-105026621336&doi=10.59429%2Face.v8i4.5748&partnerID=40&md5=57d4f175208ef6648c41cb0f53267ca7

3. Costa PM da S, Sales SLA, Pinheiro DP, Pontes LQ, Maranhão SS, Pessoa C do Ó, et al. Epigenetic reprogramming in cancer: From diagnosis to treatment. Front cell Dev Biol. 2023; 11:1116805.

4. Saeed AM, Al-Hamashi AAA. Molecular Docking, ADMET Study, Synthesis, Characterization and Preliminary Antiproliferative Activity of Potential Histone Deacetylase Inhibitors with Isoxazole as New Zinc Binding Group. Iraqi J Pharm Sci (P-ISSN 1683-3597 E-ISSN 2521-3512). 2023;32(Suppl.):188–203.

5. Al-Amily D, Mohammed MH. Design, synthesis and cytotoxicity study of primary amides as histone deacetylase inhibitors. Iraqi J Pharm Sci (P-ISSN 1683-3597 E-ISSN 2521-3512). 2019;28(2):151–8.

6. Rashid MS. Analysis of the Role of Glycogen Synthase Kinase 3 in the Mitotic Checkpoint. The University of Toledo; 2018.

7. Pradeep SD, Gopalakrishnan AK, Manoharan DK, Soumya RS, Gopalan RK, Mohanan P V. Isatin derived novel Schiff bases: An efficient pharmacophore for versatile biological applications. J Mol Struct. 2023; 1271:134121.

8. Hekal HA, Shaban E, Elshahid ZA, Abd El Salam HA, Atlam FM, Nosier AA. Design, synthesis, and anti-inflammatory evaluation of new isatin azo disperse dyes: computational studies, molecular docking, and printing performance on polyester fabrics. RSC Adv. 2026;16(26):23257–79.

9. Abdulkadir MQ, Abdulwahab AH, Al-Mudhafar MM. Synthesis and evaluating the antimicrobial activities of various adducts prepared from isatins and proline. Int J Drug Deliv Technol. 2022;12(2):682–7.

10. Da Silva JFM, Garden SJ, Pinto AC. The chemistry of isatins: a review from 1975 to 1999. J Braz Chem Soc. 2001; 12:273–324.

11.Sonawane RP, Tripathi RR. The chemistry and synthesis of 1H-indole-2, 3-dione (Isatin) and its derivatives. Int Lett Chem Phys Astron. 2013;7.

12.Pakravan P, Kashanian S, Khodaei MM, Harding FJ. Biochemical and pharmacological characterization of isatin and its derivatives: from structure to activity. Pharmacol Reports. 2013;65(2):313–35.

13.Chhajed SS, Padwal MS. Antimicrobial evaluation of some novel Schiff and Mannich bases of isatin and its derivatives with quinoline. 2010;

14.Shmidt MS, Reverdito AM, Kremenchuzky L, Perillo IA, Blanco MM. Simple and efficient microwave assisted N-alkylation of isatin. Molecules. 2008;13(4):831–40.

15.Alshams MA, Nafie MS, Ashour HF, Yassen ASA. A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020–2025). RSC Adv. 2025;15(39):32188–231.

16.Xu Z, Zhang S, Song X, Qiang M, Lv Z. Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H-1, 2, 3-triazole-isatin hybrids. Bioorg Med Chem Lett. 2017;27(16):3643–6.

17.Xu Z, Song X-F, Hu Y-Q, Qiang M, Lv Z-S. Azide-alkyne cycloaddition towards 1H-1, 2, 3-triazole-tethered gatifloxacin and isatin conjugates: design, synthesis and in vitro anti-mycobacterial evaluation. Eur J Med Chem. 2017;138:66–71.

18.Silver FP, Popp FD, Casey AC, Chakraborty DP, Cullen E, Kirsch WR, et al. Synthesis of Potential Antineoplastic Agents. XIX. Some 5-(ω-Chloroacylamino) quinolines and 4-and 5-(ω-Chloroacylamino) isoquinolines. J Med Chem. 1967;10(5):986–7.

19.Chohan ZH, Pervez H, Rauf A, Khan KM, Supuran CT. Isatin-derived antibacterial and antifungal compounds and their transition metal complexes. J Enzyme Inhib Med Chem. 2004;19(5):417–23.

20.Tarar A, Peng S, Cheema S, Peng C-A. Anticancer activity, mechanism, and delivery of allyl isothiocyanate. Bioengineering. 2022;9(9):470.

21.Sroor FM, Othman AM, Tantawy MA, Mahrous KF, El-Naggar ME. Synthesis, antimicrobial, anti-cancer and in silico studies of new urea derivatives. Bioorg Chem. 2021; 112:104953.

22.Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.

23.Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. .(2000) The protein data bank. Nucleic Acids Res. 2000;28(1):235–42.

24.Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750–9.

25.Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.

26.Kumar BK, Faheem n, Sekhar KVGC, Ojha R, Prajapati VK, Pai A, et al. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases. J Biomol Struct Dyn. 2022;40(3):1363–86.

27.Ivanova L, Tammiku-Taul J, García-Sosa AT, Sidorova Y, Saarma M, Karelson M. Molecular dynamics simulations of the interactions between glial cell line-derived neurotrophic factor family receptor GFRα1 and small-molecule ligands. ACS omega. 2018;3(9):11407–14.